We thank Dr. Kim et al. for their interest in our article and the thoughtful comments. totally agreed that not all patients benefit from EGFR tyrosine kinase inhibitors (TKIs) plus antivascular endothelial growth factor or vascular receptor regimen. For example, ACTIVE (CTONG1706) study, we observed concomitant with TP53 mutation had a prolonged progression-free survival (PFS) tendency. Because...